Information date: 3 September 2026 — A company cannot classify a China-facing generative-AI service from the model name alone. Public availability, target users, generated content, personal information, training inputs and the operator’s role determine which controls and reviews belong in the launch file.
Verified facts and scope
China’s Interim Measures for the Management of Generative Artificial Intelligence Services address services offered to the public in China. They allocate responsibilities around lawful content, training data, personal information, transparency and service governance.
An internal drafting assistant, an enterprise tool under contract and a public consumer service may create different exposure. The actual interface, user population and output path matter more than a marketing label such as “copilot” or “research preview.”
How the effect reaches operations
A wrong scope decision can delay launch or leave content and complaint controls incomplete.
Data flows affect consent, vendor contracts, retention and cross-border review.
Model or feature updates may change the service from a controlled internal tool into a public-facing function.
Decision
Proceed first with a limited use case whose users, inputs, outputs and human review are defined. Escalate public content generation, sensitive data, automated decisions or uncertain provider roles. If the operator cannot explain how a user reaches an output and how that output is corrected, pause release.
Implementation checklist
- Map every user type, interface, model provider, input source and output destination.
- Record whether the function is public, enterprise-only or internal and identify the responsible operator.
- Review training and retrieval data rights, personal-information handling and content controls.
- Test prompts that create illegal, misleading, discriminatory or personal content and document response paths.
- Define user notice, complaint, correction, logging and shutdown procedures.
- Repeat scope review when the model, audience, data source or autonomy changes.
Evidence and review
For “China generative-AI launch checklist: Separate filing, content controls and the real user journey”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Map every user type, interface, model provider, input source and output destination.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Record whether the function is public, enterprise-only or internal and identify the responsible operator.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Review training and retrieval data rights, personal-information handling and content controls.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Release criterion
The release test for “China generative-AI launch checklist: Separate filing, content controls and the real user journey” is not document volume. Each material number needs a date and denominator, each action needs an owner and trigger, and each exception needs an escalation route. When the source, operating step and limit align, minor wording differences do not justify another rewrite. If the conclusion still depends on an unverified assumption, narrow the claim or pause the affected decision until direct evidence is available.
Counter-scenario and ownership
The review must also test the opposite of the expected outcome. If “A wrong scope decision can delay launch or leave content and complaint controls incomplete.”, the record should already identify who detects it, who can pause the process, and who communicates with affected people or authorities. Direct, current evidence about the studied product, population or transaction takes priority when it conflicts with a broad market statement. Keep both the approval reason and the rejection reason. Later evidence should reopen only the affected question, not trigger an unsupported rewrite of findings that still hold.
Limits of the conclusion
This checklist is general market-entry information, not a filing determination. Sector rules, cybersecurity, data-export, algorithm, advertising and consumer obligations may also apply. Use the current Chinese text and competent advice for a real launch.
